Aptus Pharma FY26 revenue rose 89.6% to Rs 4,670.81 lakh, nearly doubling FY25 levels.
EBITDA increased 57.7% to Rs 750.32 lakh, while margin slipped to 16.06% from 19.31% YoY.
PAT grew 49.1% to Rs 461.99 lakh, margin fell to 9.89% from 12.58% YoY.
Company now offers 250+ formulations, serves 25K+ retail outlets via 200+ distributors and 10K+ doctors, targeting pan‑India presence by 2030.